- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03157401
Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty
Effects of Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty: a Prospective, Open-label, Randomized, Controlled Clinical Trial
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Background Total hip arthroplasty (THA) is extensively used in various hip diseases. Abundant blood supply at surgical area of bone tissue, intraoperative extensive cleaning, acetabular formation, femoral expansion, and medullary cavity and bone wound bleeding, will lead to extensive intraoperative and postoperative blood loss. The blood transfusion rate is high, which affects patients' rehabilitation. Previous studies have shown that 16%-69% patients required blood transfusion after first THA, which greatly affected patient's rehabilitation, and increased the risk of transfusion-related infection, hemolysis, immunosuppression, acute lung injury, and death. How to reduce perioperative blood loss in total hip arthroplasty has become a hot spot for joint surgeons.
Tranexamic acid as a synthetic antifibrinolytic drug is a synthetic analog of the amino acid lysine. Its mechanisms of action are the competitive inhibition of fibrinolytic zymogens, and noncompetitive inhibition of fibrinolytic enzymes. Tranexamic acid strongly inhibits plasmin-induced fibrin decomposition, reduces fibrinolytic system activity, to achieve local hemostasis and reduce bleeding (Appendix 1). However, the route of administration of tranexamic acid is diverse, and the best way to administer is not clear. A large number of studies have confirmed that during total knee arthroplasty and THA, intravenous application of tranexamic acid can significantly reduce postoperative blood loss, blood transfusion volume and blood transfusion rate. Intra-articular application of tranexamic acid can reduce the drainage volume of drainage tube, total blood loss, blood transfusion volume and blood transfusion rate after joint arthroplasty. Moreover, hemoglobin levels remarkably increase after surgery. More and more studies and meta-analysis have verified that tranexamic acid has a "target effect". Reasonable use of tranexamic acid does not increase the risk of deep venous thrombosis or pulmonary embolism after hip and knee arthroplasties. Simultaneously, tranexamic acid has a good potency ratio.
Adverse events
- To record adverse events during follow up, including incision pain, infection, hip pain, peripheral nerve injury, pulmonary embolism, lower extremity hematoma, deep vein thrombosis, and fixator falling off.
- If severe adverse events occur, investigators would report details, including the date of occurrence and measures taken to treat the adverse events, to the principle investigator and the institutional review board within 24 hours.
Data collection, management, analysis, open access
- Data collection: Case report forms were collected and processed using Epidata software (Epidata Association, Odense, Denmark). These data would be recorded electronically.
- Data management: Tengzhou Central People's Hospital, China would preserve all of the data regarding this trial. Only the project manager has the right to query the database file. This arrangement will not be altered.
- Data analysis: A professional statistician would statistically analyze the electronic database and create an outcome analysis report. An independent data monitoring committee would supervise and manage the trial data.
- Data open access: Anonymized trial data will be published at www.figshare.com.
Statistical analysis
- Statistical analysis would be performed using SPSS 19.0 software (IBM, Armonk, NY, USA) and would follow the intention-to-treat principle.
- Normally distributed measurement data would be expressed as means ± standard deviation and minimums and maximums. Non-normally distributed measurement data would be expressed as the lower quartile (q1) and median and upper quartiles (q3). Count data would be expressed as a percentage.
- The differences in hidden blood loss, dominant blood loss and mean blood loss in each group at intraoperative, postoperative 1 and 3 days would be compared using two-factor analysis of variance with repeated measures. Paired comparison of intergroup data would be conducted using least significant difference. Blood transfusion rate and incidence of adverse reactions in each group were compared using Pearson X2 test.
- The significance level would be α = 0.05.
Studietyp
Inskrivning (Förväntat)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Femoral head necrosis or femoral neck fracture patients undergoing the first unilateral THA
- Bilateral hips with indications for THA in patients with femoral head necrosis, but after arthroplasty on one side, the arthroplasty on the other side will be conducted when choosing a good time and physical condition allows.
- Average age: 62.52 years
- Sex ratio of males to females: 11:19
- Signed informed consent
Exclusion Criteria:
- Coagulation disorders and anemia
- History of infection on the affected extremity
- History of vascular embolization and long-term oral anticoagulant drugs
- Contraindications for tranexamic acid or anticoagulant drugs
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
intravenous infusion group
In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
|
In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Andra namn:
|
intra-articular injection group
In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
|
In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
Andra namn:
|
control group
In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
|
In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
hidden blood loss
Tidsram: at postoperative 1 and 3 days
|
Hidden blood loss was calculated by the circulation volume proposed by Gross, i.e., total erythrocyte loss is equal to preoperative total blood volume × (hematocrit preoperatively - hematocrit postoperatively 3 days).
|
at postoperative 1 and 3 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Dominant blood loss
Tidsram: at intraoperative, postoperative 1 and 3 days
|
Dominant blood loss includes intraoperative blood loss and postoperative blood loss.
Intraoperative blood loss was quantified by measuring irrigation fluid and weight measurement of surgical sponges.
Postoperative blood loss was quantified by measuring wound drainage volume and weight measurement of surgical sponges.
|
at intraoperative, postoperative 1 and 3 days
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Zhenyang Hou, Master, Tengzhou Central People's Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TengzhouCPH_01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Total höftprotesplastik
-
Zimmer BiometBiomet France SARLAvslutadTotal Hip ResurfacingFrankrike
-
Groupe Hospitalier Paris Saint JosephAktiv, inte rekryterandeErsättning, Total HipFrankrike
-
OrthoCarolina Research Institute, Inc.Presbyterian Pathology GroupAvslutad
-
Groupe Hospitalier Paris Saint JosephAvslutadAcetabulär fraktur | Total HipFrankrike
-
Istituto Ortopedico RizzoliRekryteringHip Impingement Syndrome | ProteskomplikationItalien
-
Revalesio CorporationIndragen
-
University of PittsburghAnmälan via inbjudanAcetabulär labral tår | Hip Impingement SyndromeFörenta staterna
-
National Taiwan University HospitalOkändTotal höftledsplastik | Total höftprotesplastikTaiwan
-
DePuy OrthopaedicsJohnson & Johnson Health and Wellness Solutions, Inc.AvslutadTotal knäprotesplastik; Total höftprotesplastikFörenta staterna
Kliniska prövningar på intravenous infusion group
-
Nova Scotia Health AuthorityAvslutad
-
The First Affiliated Hospital with Nanjing Medical...Wu Jieping Medical FoundationAvslutad
-
Ayşegül İşler DalgıçHorizonHar inte rekryterat ännuStress, känslomässigt | Hälsoriskbeteenden | Hälsorelaterat beteende | Hälsosam livsstil | Fysisk inaktivitet | Hälsosam kost | Hälsosam kost Index | Icke smittsamma sjukdomarKalkon
-
RenJi HospitalHar inte rekryterat ännuVätskelyhördhet | Variation av slagvolym | SVV-FloTrac | Thorax elektrisk bioimpedansKina
-
RenJi HospitalHar inte rekryterat ännuVätskelyhördhet | Variation av slagvolym | SVV-FloTrac | Thorax elektrisk bioimpedansKina
-
Dokuz Eylul UniversityHar inte rekryterat ännuGlenohumeral intern rotationsunderskott
-
Dokuz Eylul UniversityHar inte rekryterat ännuGlenohumeral intern rotationsunderskott
-
Boston Medical CenterNational Institute of Mental Health (NIMH)AvslutadPosttraumatisk stressyndromFörenta staterna
-
Hui-Hsun ChiangAvslutadUtbildningsproblem | Amning | Våld på arbetsplatsenTaiwan
-
Community Health Center of Franklin CountyMassachusetts General Hospital; Just RootsOkänd